Vertex pauses diabetes cell therapy study following two patient deaths
Vertex has pressed pause on its Phase 1/2 study of its insulin-producing cell therapy for patients with type 1 diabetes following two patient deaths that the company said were unrelated to the drug. This is the second time Vertex ’s progress on its diabetes drug has been paused.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Hannah Green Source Type: news
More News: Biotechnology | Diabetes | Diabetes Type 1 | Endocrinology | Health Management | Insulin | Study